Overview

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
We will evaluate the efficacy of PN 400 and an active comparator in patients that have Osteoarthritis of the knee.
Phase:
Phase 3
Details
Lead Sponsor:
POZEN
Treatments:
Antacids
Anti-Ulcer Agents
Celecoxib